This content is machine translated Diffuse large B-cell lymphoma T-cell-based therapy “off the shelf” Two types of T-cell-based therapy are available for refractory or relapsing diffuse large B-cell lymphoma (DLBCL): CAR T cells and bispecific antibodies. While CAR T cells have revolutionized individualized medicine…
View Post 5 min This content is machine translated Diffuse large B-cell lymphoma (DLBCL) Innovative Salvage Therapy for Advanced DLBCL Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. If left untreated, accumulations of lymphoma cells impede the function of affected organs and lead to the death…
View Post 11 min This content is machine translated Aggressive lymphomas Therapy in everyday clinical practice based on current developments Lymphoma accounts for 3.8% of all new cancer diagnoses. According to the current WHO classification, there are over 75 different lymphomentities, which are treated differently. In the treatment of diffuse… CME-Test
View Post 5 min This content is machine translated ICML 2017 in Lugano Long-term data are positive At the ICML Congress, the audience gained insight into long-term data from two phase III trials in mantle cell lymphoma and chronic lymphocytic leukemia. The new results confirm the statements…
View Post 4 min This content is machine translated Lymphomas What the family doctor needs to know At the SGIM Great Update in Interlaken, the most common problems and challenges that a family physician encounters when dealing with patients suffering from lymphoma were discussed. The only difficulty…
View Post 6 min This content is machine translated Nodal lymphoma from the pathology point of view Update for daily practice A persistent lymphadenopathy is a clear indication for further histopathological diagnosis. A detailed medical history as well as knowledge of previous diseases, manipulations and drug therapies are essential for a…
View Post 6 min This content is machine translated Chronic lymphocytic leukemia and non-Hodgkin's lymphoma Updates on the active ingredients GA101 and rituximab Three studies on chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma were discussed at the ASH in New Orleans: One was an update on the stage 1 analysis of the CLL11…
